Latest from the FDA

 
 
  • A Short Tutorial on REMS: The FDA Perspective   Dr. Gerald Dal Pan, Acting Director of the Office of Surveillance and Epidemiology at the FDA, describes the current situation with REMS.
  • Repairing Pelvic Organ Prolapse: What's Best?   What is best practice for repair of POP?
  • Statins: The Story Behind the Label Changes Are you up-to-date on the FDA's new labeling changes for the entire statin drug class? FDA's Deputy Director for Safety explains why these changes were made.
  • What To Do About Misleading Drug Ads   The FDA can't be everywhere. What is the responsibility of healthcare providers to try and rein in misleading pharmaceutical advertisements?
  • The Problem With Drug Shortages   How is the FDA responding to actual and potential drug shortages?
  • Current and Future State of Drug-Eluting Stents   Andrew Farb and Ashley B. Boam of the FDA provide a comprehensive overview of drug-eluting stents, including the state of current approvals and future developments.
  • Surgical Fires: How They Start and How to Prevent Them   In this FDA peer-to-peer video Stephanie Joseph and Dr. Kenneth Silverstein discuss his experience with surgical fires, which led to important and innovative improvements in preventive systems.
  • Simvastatin 80 mg: An FDA Expert Interview Medscape talked to the FDA's Amy Egan, MD, about drug safety communication on the 80-mg dose of simvastatin.
  • Ticagrelor: The View From the FDA Ticagrelor was approved by the FDA on July 20, 2011. Dr. Stockbridge, Director of the Division of Cardiovascular and Renal Products, discusses the issues.
  • The Changes in Sunscreen Labeling Recently the US Food and Drug Administration released significant changes in labeling requirements for sunscreen products. Are you providing the right information to your patients when they ask?
  • Are You Prescribing Unapproved Drugs?   Some drugs that are currently on the market have never been approved by the US Food and Drug Administration (FDA).
  • Safe Use of Drugs Requires Reports From Clinicians   The Safe Use Initiative is taking aim at adverse drug events and seeks input on safety issues encountered by frontline clinicians.